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Thenell & Associates is a regulatory consultancy that provides expert advice and support 
to companies that make and market genetically engineered plants for food, fiber or fuel. 
We help clients plan and execute product approval strategies and support their R&D 
programs from discovery through commercialization. Our clients include start-ups, early 
and late-stage product developers, mature multi-nationals, and universities. With more 
than 0 years of practical experience working with US federal and state regulators, we’ve 
helped two dozen companies advance their commercialization goals. 
We also do some biopesticide and biofertilizer work, and have also done work with 
genetically engineered microorganisms for industrial purposes. In 006, together with 
three colleagues in the United States and Europe, I co-founded the Agricultural BioTech 
Regulatory Network. The ABTR Network is a group of regulatory professionals serving 
the agricultural biotechnology industry from product concept through commercialization. 
It’s a network of well qualified regulatory experts who specialize in genetically engineered 
plants and plant products. Today, we have members and affiliates on four continents 
serving major ag-biotech markets (Figure ). Through the ABTR Network, we are able 
to offer clients global understanding and support typically found only in multi-national 
companies. We need to be able to offer this perspective because what is cultivated here 
in the United States doesn’t necessarily remain here in the United States.
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Specialty Crops: Premarket Approval
It is not uncommon for scientist who have deployed genetically engineered traits in spe-
cialty crops to fail to initiate the process of obtaining premarket approval, or—having 
initiated the process—have failed to complete it. Commonly heard reasons for cessation, 
from university research directors, include: 
• “It’s not the objective of our research. We are here to do the proof-of-concept, the 
discovery, to fulfill the obligations of our grant without the intent to commercial-
ize. We publish papers and then move on to the next grant.”
• “We don’t know where to start.”
• “It’s too complicated.”
• “It’s too expensive.”
• “There are intellectual property constraints.” 
• “We have concerns over product liability and stewardship—potential for lawsuits.”
• “Without a commercial partnership, there is no obvious outlet for the discovery.”
• “No mechanism exists within my university to commercialize.”
Taken together, these are daunting impediments. On the other hand, with good planning, 
the regulatory issues are not overly complicated. I will describe some of the lessons I’ve 
learned from working in ag-biotech regulations since 990 in hopes that it will de-mystify 
the product-development process and demonstrate that pre-market approval for genetic 
traits produced by public-sector researchers is possible. My intention is not to make you 
an expert, but to convince you to hire the best help you can afford when you need it.
Where We Are and How We Got Here
By some measures, biotechnology has been remarkably successful. Since commercial 
deployment in 996, global acreage has increased at double-digit rates for 7 years. It 
has been claimed that agricultural production has increased by nearly $00 billion in 
that time. Myriad environmental benefits have accrued from changes in weed and insect 
control measures, from conservation tillage, from reduced mycotoxins, etc.
Data published by the International Service for the Acquisition of Agri-biotech 
 Applications (ISAAA) indicate that 8 countries have approved some 35 unique crop/trait 
combinations to date (Figure ). And although specialty products were the very first ap-
provals, the vast majority of today’s production is limited to variants of two genetic traits 
in commodity crops. Specific numbers are hard to come by, but I submit that specialty 
crops account for less than one-tenth of one percent of the 40 million acres of GM 
crops produced in the world today.
The power of this technology isn’t finding its way to green grocers’ shops and produce 
aisles; the regulatory environment is often cited as one reason for the dichotomy between 
agronomic and specialty crops. With divergent regulatory requirements around the world, 
premarket approvals have to be acquired country-by-country. Only certain countries have 
regulatory systems in place, and only some of these have functional systems. Furthermore, 
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Figure . Agricultural BioTech Regulatory Network.
Figure . Global GM-crop status.
pre- and post-market requirements vary considerably. Global registration is necessary 
because, as said before, many of these crops move in international trade. Specialty crops 
are not necessarily an exception. In the tomato industry, for example, fresh-market pro-
duce is the primary outlet, but, additionally, tomatoes go into processing. Similar crops 
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have components that become ingredients of foods that move in international trade, 
and issues come up needing regulatory approvals in other countries. Also, only certain 
countries have functional regulatory systems and certain countries have higher impedi-
ments to commercialization than does the United States. Internationally, regulations are 
not harmonized although there are some reasonably harmonized regulatory risk-assess-
ment criteria. The net effect of this is that when amortized over the thousands of acres of 
specialty-crop deployment versus the millions of acres in agronomic crops, certain of the 
regulatory costs make it prohibitive to deploy technology in specialty crops. For this and 
various other reasons, specialty crops lag behind. I would like to help change that.
Other global instruments have to be considered (Figure 3). The Cartagena Protocol 
established minimal requirements on trans-boundary movement and use of living modified 
organisms. It’s particularly important in less-developed countries that don’t have national 
legislation governing genetically engineered organisms. Established in 003, it’s based 
on the precautionary principle, and it has some additional issues concerning advanced 
informed consent before one initiates trans-boundary movement, as well as liability and 
redress provisions for environmental contamination that are still being worked out. As 
of 03, the Cartagena Protocol has been adopted by 65 countries. But the United 
States, Australia and Canada are not signatories. Risk-analysis principles—pertaining to 
genetically engineered food—were promulgated under Codex Alimentarius also in 003; 
they are internationally recognized as meeting WTO commitments. Those principles are 
generally consistent with US safety standards and with the Biosafety Protocol. In addition 
to the WTO agreements, a number of bilateral agreements are in place to facilitate trade 
including trade in genetically engineered foods and feeds. The WTO agreements have 
been invoked in trade disputes between members with varying success.
Upcoming negotiations between the United States and Europe will probably include 
genetically engineered foods.
US Coordinated Framework
In the United States, we operate under the Coordinated Framework for Regulation of 
Biotechnology Products. Three federal agencies share primary responsibility for assur-
ing safety of genetically engineered plants and plant products, in accordance with their 
respective legal authorities:
• USDA-APHIS (US Department of Agriculture-Animal and Plant Health 
 Inspection Service)—safety of genetically engineered organisms in agriculture and 
the natural environment,
• FDA (Food and Drug Administration)—safety of foods from genetically 
 engineered organisms used for food and feed,
• EPA (Environmental Protection Agency)—safety of pesticidal substances 
 produced in genetically engineered plants or microbes.
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Figure 3. Other global instruments.
USDA-APHIS1 is the agency likely to be encountered initially when developing and 
deploying a genetically engineered plant product, in terms of environmental safety, field 
testing, and/or interstate movement. Bob Merker2 with FDA mentioned early food-safety 
assessment for novel proteins that are introduced in field testing so that, should there 
be any adventitious presence, the food/feed safety concerns would already have been 
addressed, at least at a preliminary level. And Chris Wozniak3 with EPA talked about 
the safety of biopesticides and plant incorporated protectants. This comprehensive—if 
somewhat complicated—system has worked fairly well since the mid-980s, although it 
may be argued that improvements are now needed.
Continuing Controversies
However, even after two decades of commercial use, many recent headlines have focused 
on controversies around the deployment of genetically engineered plants (Figure 4). 
Litigations over stewardship lapses and disrupted trade have cost technology providers 
hundreds of millions of dollars, with lawsuits over intellectual property rights and over 
government approvals, some of which have made their way to the Supreme Court. As a 
result, approval times for genetically engineered crops have ballooned from approximately 
6 months to over 3 years. Happily, in 0, USDA implemented process improvements 
to reduce approval times considerably. 
1Pages 4–48.
2Pages 5–60.
3Pages 3–39.
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Figure 4. Recent headlines.
Labeling
Controversy continues around labeling. In 0, Californians failed to approve a labeling 
initiative at the ballot box, and, more recently, the Senate struck down a labeling amend-
ment in their version of the Farm Bill. Some people remain deeply passionate about the 
need for labeling of foods with genetically engineered ingredients although no health or 
safety reason justifies it. The advocacy group, Center for Food Safety, claims that 5 states 
have introduced bills to require labeling or restrict genetically engineered foods.
All of these issues play some role in the decision to deploy a genetically engineered 
trait in specialty crops or not.
Product Development
Despite all of the challenges, genetic engineering still holds tremendous potential for 
improving agricultural yields in the face of continuing challenges from pests and dis-
ease, climate change, and population growth. So the question is: How does one deploy 
this technology and bring a genetically engineered product to market? The process involves 
multiple disciplines working to address various interests that are, oftentimes, not well 
aligned (Figure 5). The regulatory piece is just one discipline, the purpose of which is to 
meet all domestic and international approval requirements premarket in those countries 
wherever one intends to cultivate, to export, or to otherwise market the plant product. 
The challenge, of course, is to coordinate these efforts to achieve timely completion and 
enable product introduction to the greatest extent possible. Fulfilling regulatory require-
ments is often critical to success.
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Figure 5. Product development–.
Figure 6. Product development–.
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In the product-development scheme, the major technology providers have adopted 
some type of systematic approach to creating new crop traits (Figure 6). The process can 
be organized in stages with defined criteria that must be achieved before advancing to the 
next stage. By adopting a system of “stages and gateways,” the process is more disciplined, 
thereby helping management of risks and costs at each stage. It can transit from a gene-
discovery phase through proof-of-concept, often in a model crop and ultimately in the 
crop of interest. It moves into an early-development phase in which the trait and its utility 
are validated, generating pre-regulatory data for the crop intended for market. It advances 
to trait integration in other germplasm, with field testing to generate regulatory data, and, 
finally, into prelaunch activities, bulking up seed, and premarketing activities. Duration 
can vary. Success rate increases in accordance with decisions around event selection, and 
the number of transformants—the number of candidate lines—decreases until, at the 
end of the process, focus should be on one, maybe two, commercial events. By adopting 
this “stages and gateways” approach the process is more disciplined, and it helps manage 
costs and the risks at each stage.
Regulatory Activities
Each development stage has characteristic regulatory activities and defined criteria for 
passage to the next stage (Figure 7). The earliest stages involve preliminary analyses of 
the crop biology and the product concept, and looking at some issues that might occur 
with deployment of a particular trait in a particular crop species. At proof-of-concept, 
early work comprises evaluation of whether the active molecule or the technical effect 
has some human health or safety or environmental safety issue; also analytical tools and 
reagents are being developed, and protein production and characterization, particularly 
if additional animal testing is needed, for example. The early stages involve generating 
protein-safety data on the introduced traits—so-called “core-package” data—and sup-
porting field evaluations and testing. In the later stages, the heavy lifting begins from 
the regulatory point of view: a number of studies are needed to characterize and create 
safety data on the lead commercial transformation event—so-called “event package” 
data—assembling the registration dossiers and managing their submissions. Critically 
important decisions must be made before entering this phase, as the costs of generating 
data increase dramatically and the cost of failure at this stage can be high. Molecular 
characterization is involved as are compositional analyses, agronomic studies, effects on 
non-target organisms, animal-performance studies, and determinations of environmental 
fate and toxicology. Finally, at the prelaunch stage, dossiers are compiled and regulatory 
submissions are managed through to completion.
Much has been said about the high cost of achieving regulatory approval for genetically 
engineered crop traits. Published numbers range from $6 million to $5 million for global 
approval. A recent study quoted $35 million for global approval. Although these costs 
are real, they are inflated inasmuch as they reflect the fully loaded costs of supporting 
expensive infrastructures to support global deployment. In fact, regulatory approval can 
be obtained for considerably less—at least in order of magnitude less.
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Figure 7. Regulatory activities.
Product Design
Early in their deployment, novelty seemed to drive introductions of genetically engineered 
foods. However, it soon became clear that market pull trumps technology push. So when 
asking whether to move forward with the genetically engineered specialty crop, critical 
questions are:
• Why this?
• Why here?
• Why now?”
The market needs to be assessed efficiently and effectively. It is vitally important to “map” 
stakeholders to gauge market acceptance and vulnerabilities. Products can achieve techni-
cal success, but fail in the market because of lack of acceptance somewhere in the value 
chain; it can be an expensive lesson.
Regulatory guidance in product design is important (Figure 8). There are myriad places 
to stumble, but they are largely avoidable vis-à-vis regulatory activities. With expert and 
timely guidance, significant savings are possible in the cost of a regulatory dossier while 
maximizing the chance of timely approval. On the other hand, I have seen examples of 
products designed without regulatory input, mainly proof-of-concept projects: “We threw 
some genes in the plant, we got a great phenotype, so let’s make it a commercial product.” 
This can cause significant regulatory heartburn due to poor construct design choices or 
incomplete information. Seeking out regulatory guidance in the early stages is likely to 
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Figure 8. Regulatory guidance in product design.
be a good investment. Strategic and practical regulatory decisions should be considered 
in product design (Figure 8), including:
• New breeding techniques like precision genome editing can lead to products that 
are outside the scope of certain regulations and their associated compliance costs.
• For other genetic modifications, early regulatory input on the source of genetic 
elements, construct design, transformation and selection methods can reduce 
regulatory data costs later on.
• Conducting a detailed regulatory assessment, at the product-concept or the 
proof-of-concept phase of product development, is highly recommended.
A good-quality assessment by a consultant will identify the prospective data set, the costs 
involved, and the timeline to be expected. Once you’ve “pressure” tested your product 
design with an expert, it’s a good time to consult with your regulatory authorities.
Representatives of USDA-APHIS, FDA and EPA are an excellent resource, and each 
federal agency has a mechanism by which a developer can meet to discuss their project 
development. The purpose of such meetings is largely to confirm the regulatory strategy 
and inform the regulator(s) of the project. It is also an opportunity to confirm the scope of 
data necessary for pre-market approval before commitment to expensive studies. Depend-
ing on how novel is the crop trait or technique is to the particular agency, there should 
be several consultations during the course of product development (Figure 9). 
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Figure 9. Consultation with regulators.
Analytical Tools
Analytical tools and reagents are a vital part of preparing the “core-package” data for 
pre-market approval. Consultation with regulators is particularly important if novel 
methods have to be developed, to produce the right kind and quality of safety data. One 
also needs to make sure that these methods are validated in the matrix that you’re using, 
and under actual conditions. Good laboratory practices (GLPs) can be expensive. At a 
minimum, work by contract labs should be conducted with GLPs, including analytical 
chemistry, animal testing, compositional studies and nutrient analyses. Whether field 
work is hired out or is performed within an intramural non-GLP research program, it is 
vitally important to maintain careful records for regulatory compliance.
At each developmental stage, the transformation events created must be screened for 
various characteristics and only those meeting specifications selected so that they will 
eventually gain regulatory approval. Approval can be delayed or even derailed because 
they have not had the appropriate selection.
For regulators, transparency is particularly important. They like to see peer-reviewed lit-
erature describing performance and safety of a new trait. It contributes to their familiarity, 
and it can make their decision making appear not solely based on proprietary company 
data. Accordingly, publishing results of efficacy and other testing is recommended.
Stewardship
Good stewardship—vital to obtaining pre-market approval of genetically engineered 
crops—may be thought of internal quality-assurance procedures. Stewardship practices 
are largely, in my view, internal quality assurance procedures applied at each stage of 
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 development to ensure product integrity throughout the lifecycle. It’s important to main-
tain unique identifiers and meticulous records to ensure that the commercial product 
is nothing more or less than it is intended to be. Although good stewardship practices 
cannot eliminate human error or natural phenomena, they go a long way to minimizing 
events that lead to “front page news”; shortcutting can be costly.
In Summary
The challenges involved in bringing a new genetically engineered crop trait to market 
can be daunting. There are many possibilities for things to go terribly wrong. Regulatory 
expertise will not necessarily solve all of the impediments to achieving market success. 
On the other hand, with careful planning, regulatory approval doesn’t have to be an 
insurmountable impediment.
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